Michael Moradi-Araghi

General Partner, Sensulin

Deep tech entrepreneur turned investor, having founded several biotech companies, nanotech companies, & venture capital funds. He is a Founding General Partner at Cortado Ventures, which is investing in critical technologies in space tech, health/life sciences, logistics, and energy tech. He is also CEO of Sensulin, which is developing a next-generation insulin for diabetes. Formerly: Co-Founder and Chief Executive Officer, an ocular pharmaceutical company and specialty Contract Research Organization (eyeCRO), which was the 264th fastest growing private company in the 2009 Inc. 500; co-founded Nanopolaris (now Unidym), which was acquired in 2011 by a publicly traded South Korean company for $145 million; co-founded NanoSource, which was acquired by DuPont in 2002, largely considered the first major acquisition in the nanotech space. 2017 Young Global Leader, World Economic Forum. Kauffman Fellow (class 29), which is the premier fellowship in venture capital fund management.

About us

Engage with us

  • Sign in
  • Partner with us
  • Become a member
  • Sign up for our press releases
  • Subscribe to our newsletters
  • Contact us

Quick links

Language editions

Privacy Policy & Terms of Service

Sitemap

© 2024 World Economic Forum